Alltrna announced approval to initiate a Phase 1 clinical trial of AP003 in healthy volunteers in Australia under the TGA Clinical Trial Notification (CTN) scheme, following Human Research Ethics Committee (HREC) review.
Rachel Green, Ph.D., Chair, is an investigator at the Howard Hughes Medical Institute (HHMI) and a Bloomberg Distinguished Professor in the Department of Molecular Biology and Genetics at the Johns Hopkins University School of Medicine.
Alltrna announced a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, May 7–11 in Baltimore, and a talk and two poster presentations at TIDES USA 2024, May 14–17, digitally and in person in Boston.
Alltrna raised $109 million in Series B financing to advance its platform and first drug candidates toward clinical development for an initial indication in Stop Codon Disease.
Alltrna has an unprecedented opportunity to advance universal tRNA medicines and unify treatment across a wide range of diseases with the same underlying genetic mutations.
